Indications and uses
to soothe: • itching • flea bites • dermatitis • skin irritations • eczema
to soothe: • itching • flea bites • dermatitis • skin irritations • eczema
• pre-bathe animal with a mild shampoo and dry thoroughly • if necessary, spread coat apart with fingers to expose irritated area to expose skin • massage lotion directly on the affected area. only a thin coat is necessary • small applications at frequent intervals give best results • for long haired breeds, it may be necessary to clip hair from irritated area to expose skin • when using this product- avoid in co...
Hydrocortisone Acetate 0.50%
Anti-itch
to soothe: • itching • flea bites • dermatitis • skin irritations • eczema
For external use only. Use for all adult dogs.
and animals to avoid unintended consumption. Do not use if product appears to be tampered with.
in eyes or nose • where infection (pus) is present, since the drug may allow infection to be spread • on pregnant animals.
Not for prolonged use. Do not apply to large areas of the body.
if redness, irritation, or swelling persists or increases.
• pre-bathe animal with a mild shampoo and dry thoroughly
• if necessary, spread coat apart with fingers to expose irritated area to expose skin
• massage lotion directly on the affected area. only a thin coat is necessary
• small applications at frequent intervals give best results
• for long haired breeds, it may be necessary to clip hair from irritated area to expose skin
• when using this product- avoid in contact with the eyes.
• individual results may vary
Store product in cool. dry place. Avoid temperatures above 86F.
Deionized Water, Mineral Oil, Propylene Glycol, Isopropyl Myristate, Stearic Acid, Beeswax White, Cetyl Alcohol, Cocoamide DEA, Aloe Barbadensis Leal Juice, Carbomer, Sodium Borate, Diazolidinyl Urea, Methylparaben, Propylparaben, Fragrance.
(800) 530-2178
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYDROCORTISONE ACETATE | ACTIVE INGREDIENT | 3X7931PO74 | 6 | |
| HYDROCORTISONE | ACTIVE MOIETY | WI4X0X7BPJ | 6 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 6 | |
| CARBOMER 1342 | INACTIVE INGREDIENT | 809Y72KV36 | 6 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 6 | |
| COCO DIETHANOLAMIDE | INACTIVE INGREDIENT | 92005F972D | 6 | |
| DIAZOLIDINYL UREA | INACTIVE INGREDIENT | H5RIZ3MPW4 | 6 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 6 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 6 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 6 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 6 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 6 | |
| SODIUM BORATE | INACTIVE INGREDIENT | 91MBZ8H3QO | 6 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 6 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 6 | |
| WHITE WAX | INACTIVE INGREDIENT | 7G1J5DA97F | 6 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60754-925 | 60754-925-04 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROCORTISONE ACETATE | 3X7931PO74 | ACTIB |
| Water | 059QF0KO0R | IACT |
| MINERAL OIL | T5L8T28FGP | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| ISOPROPYL MYRISTATE | 0RE8K4LNJS | IACT |
| STEARIC ACID | 4ELV7Z65AP | IACT |
| WHITE WAX | 7G1J5DA97F | IACT |
| CETYL ALCOHOL | 936JST6JCN | IACT |
| COCO DIETHANOLAMIDE | 92005F972D | IACT |
| ALOE VERA LEAF | ZY81Z83H0X | IACT |
| CARBOMER 1342 | 809Y72KV36 | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
| DIAZOLIDINYL UREA | H5RIZ3MPW4 | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / TOPICAL | 3000 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, COATED / ORAL | 42.4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | SOLUTION / TOPICAL | NA | ||
| CARBOMER 1342 | CARBOMER COPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | 809Y72KV36 | GEL / TRANSDERMAL | 30 mg | ||
| WHITE WAX | WHITE WAX | 7G1J5DA97F | AEROSOL, FOAM / TOPICAL | 2 %w/w | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / TOPICAL | 82 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SHAMPOO / TOPICAL | 0.15 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| CARBOMER 1342 | CARBOMER COPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | 809Y72KV36 | CREAM / TOPICAL | 2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SUSPENSION / ORAL | 75 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER / ORAL | NA | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, FILM COATED / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IONTOPHORESIS | 0.1 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / ORAL | 336 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TOPICAL | 7 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | CREAM / VAGINAL | 200 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SOLUTION / TOPICAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL / TOPICAL | 19.2 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / AURICULAR (OTIC) | 56.55 %w/v | ||
| WHITE WAX | WHITE WAX | 7G1J5DA97F | LOTION / TOPICAL | 1 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAVENOUS | 6 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 63.4 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE, EXTENDED RELEASE / ORAL | 0.22 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| WHITE WAX | WHITE WAX | 7G1J5DA97F | SUPPOSITORY / RECTAL | 265 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SOLUTION / ORAL | 13 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / TOPICAL | 0.2 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / SUBLINGUAL | 9 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TRANSDERMAL | 113 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SUSPENSION / ORAL | 8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / ORAL | 388 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRA-ARTICULAR | 0.03 %w/v | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | LOTION / TOPICAL | 50 mg | ||
| WHITE WAX | WHITE WAX | 7G1J5DA97F | CREAM, AUGMENTED / TOPICAL | 10 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | SOLUTION / OPHTHALMIC | 2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / NASAL | 0.2 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | PELLET / SUBCUTANEOUS | 0.97 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hydrocortisone | HYDROCORTISONE | American Health Packaging | 506aab0d-9308-4d60-90b3-7d64952fff36 | 2026-08-31 | Warnings, Adverse reactions | Hydrocortisone |
| Hydrocortisone Acetate | HYDROCORTISONE ACETATE | Preferred Pharmaceuticals, Inc. | 247bb729-f0b6-4325-a9f8-4b46d5cda300 | 2026-08-28 | Adverse reactions | HYDROCORTISONE ACETATE |
| Hydrocortisone | HYDROCORTISONE | Amazon.com Services LLC | 5f87d7fb-f258-48b0-8b60-1055e22ebd71 | 2026-08-25 | Warnings | Hydrocortisone |
| Claravie | HYDROCORTISONE ACETATE | Gentell LLC | 598d224b-d12e-89bf-e063-6394a90a84dc | 2026-08-21 | Warnings | HYDROCORTISONE ACETATE |
| Hydrocortisone | HYDROCORTISONE | Safetec of America, Inc. | da2b3b2c-11e0-401b-bbd2-d019271d1b3d | 2026-08-13 | Warnings | Hydrocortisone |
| HYDROCORTISONE | HYDROCORTISONE | Amazon.com Services LLC | f40b4223-e81f-4cd0-bc9b-d3d33ce8cce5 | 2026-08-12 | Warnings | HYDROCORTISONE |
| Hydrocortisone | HYDROCORTISONE | Solco Healthcare LLC | 04f112e5-ec88-46c8-b675-8b4e38a86ab4 | 2026-08-11 | Warnings, Adverse reactions | Hydrocortisone |
| hydrocortisone | HYDROCORTISONE | Bryant Ranch Prepack | 484fe5e4-a058-49c0-a382-c8fc3e20c3b2 | 2026-08-04 | Warnings | hydrocortisone |
| procure | HYDROCORTISONE ACETATE | TWIN MED, LLC | 2670c9c4-66ad-40e8-a08a-582b160de39d | 2026-08-03 | Warnings | HYDROCORTISONE ACETATE |
| Hydrocortisone | HYDROCORTISONE | REMEDYREPACK INC. | f0e66726-946b-4f63-b457-2851dc69e6b4 | 2026-08-03 | Adverse reactions | Hydrocortisone |
| hydrocortisone | HYDROCORTISONE | Eywa Pharma Inc | b3f06d10-2f01-428c-88a4-505c61c87ce8 | 2026-07-25 | Warnings, Adverse reactions | hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | AKRON PHARMA INC | daad9a1e-98d2-4ce7-9d97-ac5d81905abb | 2026-07-22 | Warnings | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE LOTION | Allegis Holdings LLC | 1a27d8fa-4025-ed68-e063-6394a90a4f37 | 2026-07-08 | Warnings, Adverse reactions | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | Encube Ethicals, Inc. | 11e120e2-a1ca-477c-b474-bcbb72656705 | 2026-06-26 | Adverse reactions | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | Mylan Pharmaceuticals Inc. | bc751403-94f2-4f9d-b533-cf6186a40ceb | 2026-05-25 | Warnings, Adverse reactions | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | Bryant Ranch Prepack | 04758c46-0ca4-4852-acdc-1f8553ce2e6e | 2026-05-21 | Adverse reactions | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | Preferred Pharmaceuticals Inc. | 02ab1006-c7c8-42c9-bda8-62c9d7142521 | 2026-05-11 | Adverse reactions | Hydrocortisone |
| Hydrocortisone | HYDROCORTISONE | Preferred Pharmaceuticals, Inc. | 058bb2ff-ff51-4a3b-ba47-cb02272d0631 | 2026-05-11 | Adverse reactions | Hydrocortisone |
| hydrocortisone | HYDROCORTISONE | Preferred Pharmaceuticals Inc. | 12cd35e3-e707-4551-b778-bf615c1a8d32 | 2026-05-11 | Warnings | hydrocortisone |
| HYDROCORTISONE | HYDROCORTISONE | Preferred Pharmaceuticals Inc. | 0bbb8a63-ae1d-41d7-b201-d1b171b31f46 | 2026-05-11 | Warnings, Adverse reactions | HYDROCORTISONE |
Adverse event summaries are temporarily unavailable. Other product information remains available.